All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
In October 2018, Bastian von Tresckow and colleagues, published on behalf of the German Hodgkin Study Group (GHSG) in The Lancet Haematology, a pre-planned follow-up analysis of two GHSG trials (HD9 and HD12 [NCT00265031]), which evaluated the use of intensive first-line chemotherapy in newly-diagnosed Hodgkin lymphoma (HL) patients. The aim of this analysis was to assess whether patient outcomes are impaired after a 10- or 15-year follow-up.
The primary analyzes of the HD9 and HD12 indicated that first-line chemotherapy aids tumor control and improves survival in advanced-stage HL patients. The primary endpoint of this follow-up study was progression-free survival (PFS). Secondary endpoints included, overall survival (OS) and the incidence of second primary malignant neoplasm.
The long-term follow-up of the HD9 and HD12 studies showed that intensive first-line treatment for newly-diagnosed advanced stage HL patients maintains its PFS and OS benefits even after 10 or 15 years. The analysis also indicated that eBEACOPP is a superior regimen for advance-stage HL. Nevertheless, the authors stated that the incidence of second primary malignant neoplasms is quite high and that more tolerable treatments need to be developed for HL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox